Oragenics Takes Major Steps in Concussion Research
Oragenics, Inc. (NYSE: OGEN), a biotechnology firm dedicated to advancing treatments for brain disorders, recently announced a significant milestone in its journey towards enhancing concussion care. The company has submitted a detailed clinical trial protocol to the Health and Disability Ethics Committee (HDEC) in New Zealand. This step is crucial for the initiation of the Phase II clinical trial of ONP-002, their innovative neurosteroid therapy aimed at treating mild traumatic brain injuries (mTBI) or concussions.
This trial is poised to evaluate ONP-002, which stands as a pioneering approach in the treatment realm, specifically targeting concussion management. If approved, Oragenics plans to commence patient enrollment and expand the study's geographical presence. The trial is set to take place at Christchurch Hospital, New Zealand's largest tertiary hospital known for its comprehensive range of medical services, from emergency care to outpatient treatments. Notably, the hospital's Emergency Department is among the busiest in the region, managing over 83,000 cases annually.
Breaking New Ground in Concussion Treatment
Janet Huffman, the Interim Chief Executive Officer of Oragenics, voiced excitement about this development. She stated, "Submitting our HDEC application is a pivotal step toward advancing ONP-002 and addressing the critical need for effective concussion treatments. With patient enrollment planned in both Australia and New Zealand, we aim to broaden our global clinical footprint. We eagerly await regulatory feedback and are committed to moving closer to delivering this much-needed therapy to patients."
The need for effective treatment options for concussion is increasingly urgent, as current pharmaceutical therapies remain limited. By embarking on this clinical trial, Oragenics aims to fill this critical gap in medical care. The upcoming trials represent a first for a novel chemical drug entity being assessed for efficacy in this patient demographic.
ONP-002 is specially formulated for intranasal delivery, providing a non-invasive yet efficient method for administering medication directly to the brain. Preclinical investigations have highlighted its potential, demonstrating promising results in reducing inflammation, oxidative stress, and brain swelling, all of which are often associated with concussions. A previous Phase I clinical study also confirmed the safety and tolerability of the drug amongst healthy volunteers.
Investor Relations and Future Directions
For those interested in following Oragenics' progress in this pioneering research, they can reach out to the company's Investor Contact: Rich Cockrell, who is available at 866.889.1972 and through the email oGen@cg.capital. The company is not just resting on its laurels; they are committed to exploring advanced intranasal therapeutic options for various neurological disorders.
Oragenics is advancing not only its flagship product, ONP-002, but is also focused on developing proprietary powder formulations and enhancing drug delivery technologies. This comprehensive approach demonstrates their commitment to improving therapeutic outcomes for neurological conditions, particularly concussions.
About Oragenics, Inc.
Founded with a mission to innovate, Oragenics, Inc. is at the forefront of the biotechnology field, specifically in creating intranasal therapies aimed at neurological disorders. The company's flagship candidate, ONP-002, is making headway in the accessible treatment of mild traumatic brain injuries. As part of their broader commitment, they are also developing avant-garde delivery technologies to enhance patient care.
Frequently Asked Questions
What is ONP-002?
ONP-002 is a proprietary neurosteroid therapy developed by Oragenics, aimed at treating mild traumatic brain injuries, including concussions.
Where will the clinical trials take place?
The clinical trials are set to be conducted at Christchurch Hospital in New Zealand, a leading medical facility known for its comprehensive services.
How does intranasal delivery of ONP-002 work?
Intranasal delivery allows the drug to be administered non-invasively, providing effective medication delivery directly to the brain.
What are the expected outcomes of the clinical trials?
The trials aim to evaluate the efficacy of ONP-002 in reducing concussion symptoms and improving patient outcomes.
Is there a current treatment available for concussions?
Currently, there are no established pharmaceutical therapies specifically for treating concussions, highlighting the significance of ONP-002's development.
